Envestnet Portfolio Solutions Inc. Has $1.73 Million Stock Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Envestnet Portfolio Solutions Inc. grew its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 227.4% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 4,345 shares of the biopharmaceutical company’s stock after buying an additional 3,018 shares during the quarter. Envestnet Portfolio Solutions Inc.’s holdings in Alnylam Pharmaceuticals were worth $1,728,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in ALNY. Brighton Jones LLC acquired a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at $243,000. Geneos Wealth Management Inc. raised its stake in shares of Alnylam Pharmaceuticals by 372.3% in the 1st quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company’s stock valued at $60,000 after buying an additional 175 shares in the last quarter. Flow Traders U.S. LLC acquired a new position in shares of Alnylam Pharmaceuticals in the 2nd quarter valued at $241,000. Daiwa Securities Group Inc. raised its stake in shares of Alnylam Pharmaceuticals by 0.3% in the 2nd quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock valued at $4,220,000 after buying an additional 35 shares in the last quarter. Finally, NewEdge Advisors LLC raised its stake in shares of Alnylam Pharmaceuticals by 70,300.0% in the 2nd quarter. NewEdge Advisors LLC now owns 704 shares of the biopharmaceutical company’s stock valued at $229,000 after buying an additional 703 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Insider Activity

In other Alnylam Pharmaceuticals news, insider Melissa Mclaughlin sold 2,286 shares of the stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $330.42, for a total transaction of $755,340.12. Following the sale, the insider owned 9,443 shares of the company’s stock, valued at $3,120,156.06. This represents a 19.49% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Yvonne Greenstreet sold 6,799 shares of the stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $327.65, for a total transaction of $2,227,692.35. Following the sale, the chief executive officer directly owned 98,628 shares in the company, valued at approximately $32,315,464.20. This represents a 6.45% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 21,255 shares of company stock worth $6,930,337. 0.86% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Trading Down 1.0%

Shares of Alnylam Pharmaceuticals stock opened at $297.45 on Friday. The stock has a market capitalization of $39.71 billion, a P/E ratio of 81.27 and a beta of 0.31. The company has a quick ratio of 3.06, a current ratio of 3.13 and a debt-to-equity ratio of 0.94. The company has a 50-day simple moving average of $311.16 and a 200 day simple moving average of $359.49. Alnylam Pharmaceuticals, Inc. has a 12-month low of $284.19 and a 12-month high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.87 by $1.12. The business had revenue of $1.17 billion during the quarter, compared to analysts’ expectations of $1.12 billion. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The firm’s revenue for the quarter was up 96.4% on a year-over-year basis. During the same quarter last year, the company posted ($0.44) EPS. Research analysts expect that Alnylam Pharmaceuticals, Inc. will post 7.36 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on ALNY shares. Bank of America restated a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Thursday, February 12th. HC Wainwright reiterated a “buy” rating and set a $510.00 target price on shares of Alnylam Pharmaceuticals in a research report on Tuesday, May 5th. Needham & Company LLC dropped their target price on shares of Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating for the company in a research report on Thursday, February 12th. Truist Financial dropped their target price on shares of Alnylam Pharmaceuticals from $515.00 to $505.00 and set a “buy” rating for the company in a research report on Monday, April 13th. Finally, Jefferies Financial Group reiterated a “hold” rating and set a $330.00 target price (down from $522.00) on shares of Alnylam Pharmaceuticals in a research report on Monday, March 16th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have issued a Hold rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $463.13.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.